| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 35 | 2023 | 2214 | 5.450 |
Why?
|
| Liver Neoplasms | 41 | 2023 | 4253 | 4.510 |
Why?
|
| Angiogenesis Inhibitors | 43 | 2022 | 2038 | 3.370 |
Why?
|
| Neovascularization, Pathologic | 45 | 2022 | 2635 | 3.040 |
Why?
|
| Phenylurea Compounds | 8 | 2020 | 528 | 2.550 |
Why?
|
| Cholangiocarcinoma | 8 | 2022 | 516 | 2.030 |
Why?
|
| Niacinamide | 6 | 2020 | 417 | 1.980 |
Why?
|
| Vascular Endothelial Growth Factor A | 41 | 2022 | 3508 | 1.960 |
Why?
|
| Tumor Microenvironment | 23 | 2023 | 3586 | 1.870 |
Why?
|
| Receptors, CXCR4 | 10 | 2022 | 726 | 1.830 |
Why?
|
| Bile Duct Neoplasms | 7 | 2022 | 567 | 1.600 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 12 | 2019 | 546 | 1.580 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2023 | 11524 | 1.200 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 14 | 2019 | 552 | 1.200 |
Why?
|
| Immunotherapy | 15 | 2022 | 4445 | 1.190 |
Why?
|
| Glioblastoma | 23 | 2020 | 3481 | 1.150 |
Why?
|
| Quinazolines | 15 | 2017 | 1356 | 1.050 |
Why?
|
| Chemokine CXCL12 | 8 | 2017 | 464 | 1.040 |
Why?
|
| Neovascularization, Physiologic | 9 | 2013 | 1351 | 1.010 |
Why?
|
| Neoplasms | 31 | 2022 | 21683 | 0.960 |
Why?
|
| Protein Kinase Inhibitors | 18 | 2022 | 5535 | 0.920 |
Why?
|
| Neoplasm Metastasis | 14 | 2017 | 4851 | 0.890 |
Why?
|
| Rectal Neoplasms | 10 | 2012 | 1206 | 0.830 |
Why?
|
| Pancreatic Neoplasms | 17 | 2023 | 5256 | 0.830 |
Why?
|
| Pyridines | 6 | 2020 | 2825 | 0.800 |
Why?
|
| Endothelial Cells | 19 | 2022 | 3479 | 0.780 |
Why?
|
| Antineoplastic Agents | 30 | 2018 | 13695 | 0.770 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2020 | 178 | 0.770 |
Why?
|
| Carcinoma, Pancreatic Ductal | 6 | 2022 | 1634 | 0.760 |
Why?
|
| Stromal Cells | 7 | 2014 | 1355 | 0.750 |
Why?
|
| Anilides | 3 | 2019 | 408 | 0.720 |
Why?
|
| Brain Neoplasms | 23 | 2022 | 8863 | 0.700 |
Why?
|
| Chemokine CXCL10 | 1 | 2020 | 304 | 0.700 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2021 | 191 | 0.680 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 10 | 2017 | 664 | 0.670 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2021 | 520 | 0.660 |
Why?
|
| Quantum Dots | 3 | 2015 | 172 | 0.630 |
Why?
|
| Fluorouracil | 9 | 2023 | 1619 | 0.620 |
Why?
|
| Liver Cirrhosis | 4 | 2022 | 1863 | 0.590 |
Why?
|
| Neoplasms, Experimental | 7 | 2019 | 1276 | 0.590 |
Why?
|
| CD8-Positive T-Lymphocytes | 8 | 2023 | 4479 | 0.580 |
Why?
|
| Antibodies, Monoclonal | 13 | 2021 | 9274 | 0.560 |
Why?
|
| Vascular Endothelial Growth Factors | 5 | 2012 | 772 | 0.550 |
Why?
|
| Nanomedicine | 2 | 2022 | 304 | 0.550 |
Why?
|
| Bone Marrow Cells | 9 | 2011 | 2513 | 0.540 |
Why?
|
| Animals | 92 | 2022 | 168757 | 0.530 |
Why?
|
| Adenocarcinoma | 11 | 2022 | 6364 | 0.530 |
Why?
|
| Antibodies | 5 | 2020 | 2460 | 0.530 |
Why?
|
| Lung Neoplasms | 15 | 2021 | 13102 | 0.530 |
Why?
|
| Mice | 64 | 2022 | 81183 | 0.500 |
Why?
|
| Receptors, CXCR | 2 | 2014 | 52 | 0.500 |
Why?
|
| Deoxycytidine | 2 | 2020 | 826 | 0.500 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2018 | 578 | 0.480 |
Why?
|
| Myeloid Cells | 4 | 2014 | 810 | 0.480 |
Why?
|
| Combined Modality Therapy | 9 | 2022 | 8642 | 0.480 |
Why?
|
| Neoplasm Proteins | 5 | 2017 | 3703 | 0.460 |
Why?
|
| Humans | 166 | 2023 | 744343 | 0.460 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2017 | 188 | 0.460 |
Why?
|
| Receptors, Chemokine | 2 | 2014 | 669 | 0.450 |
Why?
|
| Blood Vessels | 7 | 2011 | 1125 | 0.450 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 1676 | 0.440 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2014 | 640 | 0.430 |
Why?
|
| Cell Line, Tumor | 20 | 2022 | 16689 | 0.420 |
Why?
|
| Losartan | 4 | 2023 | 299 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2020 | 9239 | 0.410 |
Why?
|
| Benzimidazoles | 1 | 2017 | 850 | 0.400 |
Why?
|
| Flow Cytometry | 8 | 2013 | 5974 | 0.390 |
Why?
|
| Radiosurgery | 2 | 2022 | 1329 | 0.390 |
Why?
|
| Drug Delivery Systems | 5 | 2018 | 2219 | 0.380 |
Why?
|
| Lymphopenia | 2 | 2023 | 285 | 0.360 |
Why?
|
| Hyperoxia | 2 | 2009 | 262 | 0.360 |
Why?
|
| Nanoparticles | 3 | 2019 | 1905 | 0.350 |
Why?
|
| Disease-Free Survival | 12 | 2017 | 6895 | 0.340 |
Why?
|
| Neoplasm Transplantation | 9 | 2013 | 2085 | 0.340 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2022 | 295 | 0.340 |
Why?
|
| Endothelium, Vascular | 3 | 2007 | 4456 | 0.340 |
Why?
|
| Neoadjuvant Therapy | 11 | 2023 | 2728 | 0.330 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 990 | 0.330 |
Why?
|
| T-Lymphocytes | 5 | 2022 | 10180 | 0.320 |
Why?
|
| Lung | 6 | 2011 | 9856 | 0.320 |
Why?
|
| Breast Neoplasms | 13 | 2021 | 20822 | 0.320 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2016 | 5221 | 0.310 |
Why?
|
| Liver | 4 | 2022 | 7474 | 0.310 |
Why?
|
| Mice, SCID | 13 | 2017 | 2716 | 0.280 |
Why?
|
| Neoplastic Cells, Circulating | 7 | 2018 | 934 | 0.280 |
Why?
|
| Angiogenic Proteins | 3 | 2022 | 104 | 0.280 |
Why?
|
| Dendritic Cells | 2 | 2021 | 2725 | 0.270 |
Why?
|
| Capillaries | 1 | 2009 | 773 | 0.270 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2727 | 0.260 |
Why?
|
| Ribonuclease, Pancreatic | 2 | 2016 | 154 | 0.260 |
Why?
|
| Acute Lung Injury | 1 | 2009 | 380 | 0.260 |
Why?
|
| Pyrroles | 5 | 2015 | 1146 | 0.260 |
Why?
|
| Carbon Tetrachloride | 2 | 2015 | 64 | 0.250 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2018 | 270 | 0.250 |
Why?
|
| Photography | 1 | 2008 | 520 | 0.250 |
Why?
|
| Antibodies, Neoplasm | 2 | 2016 | 286 | 0.250 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2018 | 599 | 0.240 |
Why?
|
| Fibroblasts | 2 | 2012 | 4161 | 0.240 |
Why?
|
| Neurofibromatosis 2 | 2 | 2019 | 380 | 0.240 |
Why?
|
| Mice, Inbred C3H | 3 | 2015 | 964 | 0.240 |
Why?
|
| Vesicular Transport Proteins | 2 | 2018 | 377 | 0.240 |
Why?
|
| Cell Count | 3 | 2010 | 1856 | 0.240 |
Why?
|
| Survival Rate | 11 | 2021 | 12788 | 0.240 |
Why?
|
| Neuroma, Acoustic | 2 | 2019 | 451 | 0.240 |
Why?
|
| Tumor Cells, Cultured | 12 | 2021 | 6314 | 0.230 |
Why?
|
| Prognosis | 17 | 2022 | 29063 | 0.230 |
Why?
|
| Transplantation, Heterologous | 7 | 2015 | 2382 | 0.230 |
Why?
|
| Indoles | 5 | 2015 | 1839 | 0.230 |
Why?
|
| Cerebellar Neoplasms | 2 | 2022 | 587 | 0.230 |
Why?
|
| Stomach Neoplasms | 3 | 2019 | 1333 | 0.220 |
Why?
|
| Preoperative Care | 1 | 2012 | 2250 | 0.220 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2022 | 2948 | 0.220 |
Why?
|
| Microscopy | 3 | 2022 | 903 | 0.220 |
Why?
|
| Medulloblastoma | 2 | 2022 | 683 | 0.220 |
Why?
|
| Female | 65 | 2022 | 380194 | 0.220 |
Why?
|
| Male | 64 | 2022 | 350118 | 0.220 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2022 | 41 | 0.220 |
Why?
|
| Histamine H1 Antagonists | 1 | 2003 | 100 | 0.220 |
Why?
|
| Aged | 41 | 2022 | 163280 | 0.220 |
Why?
|
| Growth Substances | 1 | 2005 | 784 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2021 | 5172 | 0.210 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2022 | 841 | 0.200 |
Why?
|
| Middle Aged | 46 | 2022 | 213383 | 0.200 |
Why?
|
| Sarcoma | 4 | 2015 | 1897 | 0.200 |
Why?
|
| Histamine H2 Antagonists | 1 | 2003 | 165 | 0.200 |
Why?
|
| Maximum Tolerated Dose | 5 | 2022 | 892 | 0.200 |
Why?
|
| Interleukin-12 | 3 | 2000 | 579 | 0.200 |
Why?
|
| Macrophages | 5 | 2016 | 5655 | 0.200 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2010 | 3386 | 0.200 |
Why?
|
| Neuropilin-1 | 2 | 2013 | 90 | 0.190 |
Why?
|
| Tissue Engineering | 4 | 2015 | 1880 | 0.190 |
Why?
|
| Colorectal Neoplasms | 3 | 2021 | 6773 | 0.190 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 916 | 0.190 |
Why?
|
| Receptor, erbB-2 | 5 | 2021 | 2416 | 0.190 |
Why?
|
| Stem Cells | 4 | 2011 | 3567 | 0.190 |
Why?
|
| Oncolytic Virotherapy | 2 | 2022 | 498 | 0.190 |
Why?
|
| HMGB1 Protein | 1 | 2022 | 133 | 0.190 |
Why?
|
| Brain Edema | 4 | 2009 | 617 | 0.190 |
Why?
|
| Interleukin-6 | 6 | 2018 | 3200 | 0.180 |
Why?
|
| Genes, p53 | 2 | 2002 | 755 | 0.180 |
Why?
|
| Adult | 39 | 2022 | 214055 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 648 | 0.180 |
Why?
|
| Radiation Oncology | 2 | 2020 | 555 | 0.170 |
Why?
|
| Computer Simulation | 1 | 2013 | 6196 | 0.170 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2022 | 1660 | 0.170 |
Why?
|
| Treatment Outcome | 20 | 2022 | 63114 | 0.170 |
Why?
|
| Disease Progression | 8 | 2021 | 13284 | 0.170 |
Why?
|
| RNA, Messenger | 6 | 2022 | 13033 | 0.170 |
Why?
|
| Fasciola hepatica | 2 | 2020 | 15 | 0.170 |
Why?
|
| Oxygen | 4 | 2022 | 4189 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2016 | 6538 | 0.160 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2018 | 52 | 0.160 |
Why?
|
| Leucovorin | 4 | 2023 | 628 | 0.160 |
Why?
|
| Cerebellum | 2 | 2017 | 1488 | 0.160 |
Why?
|
| Tyrosine | 1 | 2022 | 1461 | 0.160 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2021 | 451 | 0.150 |
Why?
|
| Capillary Permeability | 2 | 2019 | 798 | 0.150 |
Why?
|
| Pyridazines | 1 | 2019 | 202 | 0.150 |
Why?
|
| Spheroids, Cellular | 1 | 2019 | 351 | 0.150 |
Why?
|
| Angiopoietins | 1 | 2017 | 80 | 0.150 |
Why?
|
| Mice, Nude | 6 | 2019 | 3689 | 0.150 |
Why?
|
| Pancreatectomy | 1 | 2022 | 804 | 0.150 |
Why?
|
| Clinical Trials as Topic | 8 | 2020 | 7913 | 0.150 |
Why?
|
| CA-19-9 Antigen | 2 | 2014 | 111 | 0.150 |
Why?
|
| Esophagogastric Junction | 1 | 2019 | 313 | 0.150 |
Why?
|
| Adenoviridae | 5 | 2006 | 1099 | 0.150 |
Why?
|
| Dacarbazine | 3 | 2015 | 566 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2014 | 4554 | 0.150 |
Why?
|
| Models, Animal | 4 | 2012 | 2171 | 0.150 |
Why?
|
| Lymphocyte Subsets | 1 | 2018 | 315 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2016 | 63 | 0.140 |
Why?
|
| Opisthorchis | 1 | 2016 | 2 | 0.140 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 310 | 0.140 |
Why?
|
| Opisthorchiasis | 1 | 2016 | 4 | 0.140 |
Why?
|
| Perfusion Imaging | 2 | 2016 | 195 | 0.140 |
Why?
|
| Esophageal Neoplasms | 2 | 2019 | 1583 | 0.140 |
Why?
|
| Receptor, erbB-3 | 1 | 2017 | 142 | 0.140 |
Why?
|
| Disease Models, Animal | 7 | 2022 | 18029 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2018 | 8428 | 0.140 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2020 | 880 | 0.130 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2014 | 349 | 0.130 |
Why?
|
| Metalloporphyrins | 1 | 2015 | 41 | 0.130 |
Why?
|
| Biomedical Research | 2 | 2009 | 3309 | 0.130 |
Why?
|
| Aged, 80 and over | 12 | 2022 | 57776 | 0.130 |
Why?
|
| Snake Venoms | 1 | 2015 | 39 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2021 | 1270 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 13 | 2022 | 21827 | 0.130 |
Why?
|
| Piperidines | 2 | 2015 | 1602 | 0.130 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2015 | 49 | 0.130 |
Why?
|
| Cytomegalovirus | 1 | 2020 | 732 | 0.130 |
Why?
|
| Cerebellar Diseases | 1 | 2017 | 226 | 0.130 |
Why?
|
| Maytansine | 1 | 2015 | 80 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 1 | 2022 | 1526 | 0.130 |
Why?
|
| Cell Movement | 6 | 2014 | 5217 | 0.130 |
Why?
|
| Pregnancy Proteins | 2 | 2013 | 229 | 0.130 |
Why?
|
| Trans-Activators | 3 | 2004 | 2924 | 0.130 |
Why?
|
| Immune System | 2 | 2019 | 805 | 0.130 |
Why?
|
| Nitric Oxide | 1 | 2004 | 2132 | 0.130 |
Why?
|
| Benzylamines | 2 | 2018 | 223 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 7279 | 0.130 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 39050 | 0.130 |
Why?
|
| Heterocyclic Compounds | 2 | 2018 | 249 | 0.130 |
Why?
|
| Micelles | 1 | 2015 | 203 | 0.120 |
Why?
|
| Neuroblastoma | 1 | 2022 | 1226 | 0.120 |
Why?
|
| Radiation Tolerance | 1 | 2017 | 486 | 0.120 |
Why?
|
| Cisplatin | 1 | 2020 | 1662 | 0.120 |
Why?
|
| Fascioliasis | 1 | 2013 | 14 | 0.120 |
Why?
|
| Immunohistochemistry | 9 | 2016 | 11366 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2022 | 2109 | 0.120 |
Why?
|
| Inflammation | 2 | 2012 | 10638 | 0.120 |
Why?
|
| Antibodies, Bispecific | 1 | 2016 | 164 | 0.120 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2013 | 26 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1038 | 0.120 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2014 | 180 | 0.120 |
Why?
|
| TRPM Cation Channels | 1 | 2014 | 140 | 0.110 |
Why?
|
| Imidazoles | 1 | 2019 | 1206 | 0.110 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2015 | 1736 | 0.110 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2015 | 241 | 0.110 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 3 | 2017 | 271 | 0.110 |
Why?
|
| Mice, Transgenic | 6 | 2015 | 9734 | 0.110 |
Why?
|
| Up-Regulation | 3 | 2011 | 4217 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2004 | 245 | 0.110 |
Why?
|
| Phenotype | 6 | 2009 | 16365 | 0.110 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 2015 | 0.110 |
Why?
|
| Immunoconjugates | 1 | 2020 | 901 | 0.110 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 684 | 0.110 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2019 | 712 | 0.110 |
Why?
|
| Killer Cells, Natural | 2 | 2018 | 2133 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 1821 | 0.100 |
Why?
|
| Parabiosis | 1 | 2012 | 65 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 2540 | 0.100 |
Why?
|
| Epigenomics | 1 | 2017 | 903 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 2938 | 0.100 |
Why?
|
| Radiotherapy Dosage | 5 | 2023 | 2879 | 0.100 |
Why?
|
| Quinolines | 1 | 2016 | 732 | 0.100 |
Why?
|
| Anesthesia | 1 | 2003 | 1561 | 0.100 |
Why?
|
| Photons | 1 | 2015 | 588 | 0.100 |
Why?
|
| Genes, ras | 1 | 2014 | 690 | 0.100 |
Why?
|
| Camptothecin | 2 | 2012 | 576 | 0.100 |
Why?
|
| Benzenesulfonates | 1 | 2012 | 169 | 0.100 |
Why?
|
| Gadolinium DTPA | 1 | 2014 | 836 | 0.100 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2014 | 503 | 0.090 |
Why?
|
| Extracellular Fluid | 1 | 2012 | 167 | 0.090 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2011 | 182 | 0.090 |
Why?
|
| Receptor, TIE-2 | 3 | 2019 | 178 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2019 | 3870 | 0.090 |
Why?
|
| Chemokine CXCL6 | 1 | 2009 | 13 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 6489 | 0.090 |
Why?
|
| Signal Transduction | 6 | 2022 | 23403 | 0.090 |
Why?
|
| Vascular Diseases | 2 | 2015 | 1161 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2003 | 1097 | 0.090 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 1097 | 0.090 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 399 | 0.090 |
Why?
|
| Interleukin-1beta | 2 | 2012 | 972 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2009 | 251 | 0.090 |
Why?
|
| Cell Survival | 3 | 2010 | 5882 | 0.090 |
Why?
|
| Whole-Body Irradiation | 1 | 2010 | 449 | 0.090 |
Why?
|
| Gene Transfer Techniques | 3 | 2004 | 1224 | 0.090 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2018 | 2737 | 0.080 |
Why?
|
| Interleukin-8 | 1 | 2012 | 690 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 11124 | 0.080 |
Why?
|
| ras Proteins | 1 | 2014 | 1060 | 0.080 |
Why?
|
| Adenovirus E1A Proteins | 2 | 2006 | 76 | 0.080 |
Why?
|
| Smad4 Protein | 3 | 2004 | 163 | 0.080 |
Why?
|
| E-Selectin | 1 | 2011 | 579 | 0.080 |
Why?
|
| Hearing Loss | 1 | 2016 | 765 | 0.080 |
Why?
|
| Cell Division | 4 | 2004 | 4568 | 0.080 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 933 | 0.080 |
Why?
|
| Survival Analysis | 7 | 2019 | 10252 | 0.080 |
Why?
|
| Hematologic Tests | 1 | 2009 | 240 | 0.080 |
Why?
|
| Phthalazines | 1 | 2010 | 363 | 0.080 |
Why?
|
| Colonic Neoplasms | 2 | 2015 | 2541 | 0.080 |
Why?
|
| Cytokines | 4 | 2019 | 7322 | 0.080 |
Why?
|
| Cell Line | 4 | 2017 | 15997 | 0.080 |
Why?
|
| DNA-Binding Proteins | 3 | 2004 | 9648 | 0.080 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 2 | 2020 | 188 | 0.080 |
Why?
|
| Paracrine Communication | 2 | 2013 | 277 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2010 | 697 | 0.080 |
Why?
|
| Rats | 3 | 2009 | 24260 | 0.080 |
Why?
|
| Hepatocytes | 1 | 2014 | 1211 | 0.080 |
Why?
|
| Karnofsky Performance Status | 2 | 2019 | 173 | 0.080 |
Why?
|
| Cell Cycle | 1 | 2016 | 2967 | 0.080 |
Why?
|
| Mice, Knockout | 5 | 2016 | 14557 | 0.070 |
Why?
|
| Protons | 2 | 2023 | 1127 | 0.070 |
Why?
|
| Lymphangiosarcoma | 1 | 2006 | 13 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2016 | 3557 | 0.070 |
Why?
|
| Organoplatinum Compounds | 2 | 2019 | 408 | 0.070 |
Why?
|
| Osteolysis, Essential | 1 | 2006 | 30 | 0.070 |
Why?
|
| Zebrafish Proteins | 1 | 2013 | 1005 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 3772 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2013 | 689 | 0.070 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2009 | 625 | 0.070 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1692 | 0.070 |
Why?
|
| Proteins | 1 | 2002 | 6103 | 0.070 |
Why?
|
| Nitrogen | 1 | 2008 | 344 | 0.070 |
Why?
|
| Skin Transplantation | 1 | 2012 | 1074 | 0.070 |
Why?
|
| Piperazines | 1 | 2017 | 2488 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 730 | 0.070 |
Why?
|
| Cell Proliferation | 7 | 2022 | 10481 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 4 | 2010 | 2765 | 0.070 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 1736 | 0.070 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 2187 | 0.070 |
Why?
|
| Disease | 1 | 2011 | 680 | 0.070 |
Why?
|
| Obesity | 3 | 2018 | 12745 | 0.070 |
Why?
|
| Neurons | 1 | 2005 | 9338 | 0.070 |
Why?
|
| Platelet Adhesiveness | 1 | 2006 | 161 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 4386 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 2 | 2022 | 2007 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 9959 | 0.060 |
Why?
|
| Blotting, Western | 4 | 2015 | 5179 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 4933 | 0.060 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 2924 | 0.060 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 708 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2014 | 3748 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 2 | 2009 | 1376 | 0.060 |
Why?
|
| Gelatinases | 1 | 2003 | 94 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3474 | 0.060 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2003 | 67 | 0.060 |
Why?
|
| Cell Differentiation | 2 | 2016 | 11483 | 0.060 |
Why?
|
| Glioma | 1 | 2018 | 3401 | 0.060 |
Why?
|
| Immunoglobulin G | 2 | 2013 | 4560 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 10943 | 0.060 |
Why?
|
| Models, Biological | 3 | 2011 | 9583 | 0.060 |
Why?
|
| Androgen Antagonists | 1 | 2012 | 1377 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 4751 | 0.060 |
Why?
|
| Histamine Release | 1 | 2003 | 142 | 0.060 |
Why?
|
| Receptors, Death Domain | 1 | 2022 | 32 | 0.060 |
Why?
|
| Prospective Studies | 6 | 2020 | 53288 | 0.060 |
Why?
|
| Lung Injury | 1 | 2008 | 436 | 0.050 |
Why?
|
| Vesiculovirus | 1 | 2022 | 50 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2003 | 318 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2009 | 2455 | 0.050 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2003 | 171 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 3798 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 20129 | 0.050 |
Why?
|
| 3T3 Cells | 2 | 2003 | 1101 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2022 | 142 | 0.050 |
Why?
|
| Transfection | 4 | 2006 | 5892 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2021 | 3206 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2007 | 1770 | 0.050 |
Why?
|
| Premedication | 1 | 2003 | 258 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 2494 | 0.050 |
Why?
|
| Angiotensins | 1 | 2022 | 151 | 0.050 |
Why?
|
| Time Factors | 5 | 2018 | 40075 | 0.050 |
Why?
|
| Cell Transplantation | 1 | 2003 | 477 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 3 | 2013 | 1799 | 0.050 |
Why?
|
| Kinetics | 1 | 2009 | 6473 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2015 | 2734 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2007 | 1318 | 0.050 |
Why?
|
| Membrane Proteins | 3 | 2014 | 7880 | 0.050 |
Why?
|
| Ligands | 2 | 2009 | 3282 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2013 | 4026 | 0.050 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2010 | 1363 | 0.050 |
Why?
|
| Skin Tests | 1 | 2003 | 613 | 0.050 |
Why?
|
| Young Adult | 7 | 2019 | 56430 | 0.050 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2000 | 15 | 0.050 |
Why?
|
| Growth Hormone | 1 | 2022 | 705 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2019 | 35421 | 0.040 |
Why?
|
| Virus Replication | 2 | 2006 | 2534 | 0.040 |
Why?
|
| Metformin | 2 | 2018 | 835 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2020 | 2649 | 0.040 |
Why?
|
| Thailand | 1 | 2020 | 296 | 0.040 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 513 | 0.040 |
Why?
|
| Blood Platelets | 2 | 2010 | 2508 | 0.040 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 85 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2004 | 1401 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2019 | 2505 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2004 | 1730 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2017 | 3913 | 0.040 |
Why?
|
| P-Selectin | 1 | 2001 | 600 | 0.040 |
Why?
|
| Protein Phosphatase 2 | 1 | 2020 | 229 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 793 | 0.040 |
Why?
|
| Peptides | 1 | 2011 | 4409 | 0.040 |
Why?
|
| Ecosystem | 1 | 2023 | 474 | 0.040 |
Why?
|
| Research | 1 | 2007 | 1999 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2021 | 426 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2022 | 873 | 0.040 |
Why?
|
| Chloroform | 1 | 2018 | 28 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 11031 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 12261 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 8301 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 2020 | 391 | 0.040 |
Why?
|
| Hepatic Stellate Cells | 1 | 2018 | 109 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2009 | 3279 | 0.040 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2017 | 141 | 0.040 |
Why?
|
| Hyperbilirubinemia | 1 | 2017 | 77 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 4838 | 0.040 |
Why?
|
| Adipocytes | 1 | 2003 | 1184 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 3479 | 0.040 |
Why?
|
| Monocytes | 1 | 2006 | 2596 | 0.030 |
Why?
|
| Epistaxis | 1 | 2017 | 111 | 0.030 |
Why?
|
| Models, Cardiovascular | 2 | 2012 | 996 | 0.030 |
Why?
|
| Intestinal Fistula | 1 | 2017 | 140 | 0.030 |
Why?
|
| Cytotoxins | 1 | 2016 | 153 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2003 | 3002 | 0.030 |
Why?
|
| Angiopoietin-2 | 1 | 2017 | 173 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2013 | 3701 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2020 | 541 | 0.030 |
Why?
|
| Pancreas | 1 | 2003 | 1686 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2021 | 4420 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2023 | 1613 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2003 | 2751 | 0.030 |
Why?
|
| Anaphylaxis | 1 | 2003 | 746 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2003 | 3616 | 0.030 |
Why?
|
| Palladium | 1 | 2015 | 65 | 0.030 |
Why?
|
| Capsules | 1 | 2015 | 196 | 0.030 |
Why?
|
| Cell Hypoxia | 2 | 2009 | 675 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2016 | 424 | 0.030 |
Why?
|
| Intestinal Perforation | 1 | 2017 | 253 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2023 | 2617 | 0.030 |
Why?
|
| Menthol | 1 | 2014 | 26 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 627 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2020 | 956 | 0.030 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 5524 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2002 | 1222 | 0.030 |
Why?
|
| Gene Expression Profiling | 4 | 2015 | 9438 | 0.030 |
Why?
|
| Stomach Diseases | 1 | 2015 | 134 | 0.030 |
Why?
|
| Extracellular Matrix | 2 | 2016 | 1741 | 0.030 |
Why?
|
| Apoptosis | 3 | 2020 | 9727 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2015 | 563 | 0.030 |
Why?
|
| Polyps | 1 | 2015 | 189 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2006 | 3461 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2020 | 1366 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 2016 | 624 | 0.030 |
Why?
|
| Biodiversity | 1 | 2016 | 341 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 2503 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2004 | 2148 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 2849 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 2016 | 491 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2021 | 1809 | 0.030 |
Why?
|
| CpG Islands | 1 | 2017 | 1172 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2013 | 206 | 0.030 |
Why?
|
| Wound Healing | 1 | 2004 | 2785 | 0.030 |
Why?
|
| Metagenome | 1 | 2016 | 418 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 12354 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2017 | 2327 | 0.030 |
Why?
|
| Metagenomics | 1 | 2016 | 428 | 0.030 |
Why?
|
| RNA | 1 | 2023 | 2749 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 767 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 954 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2020 | 40561 | 0.030 |
Why?
|
| Lymphoma | 1 | 2001 | 1877 | 0.030 |
Why?
|
| Hemoglobins | 2 | 2010 | 1534 | 0.030 |
Why?
|
| Albumins | 1 | 2015 | 569 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2015 | 2645 | 0.030 |
Why?
|
| Leukocytes | 2 | 2010 | 2043 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2014 | 371 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2016 | 1950 | 0.030 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 6234 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2016 | 6386 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 2011 | 3144 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 801 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2013 | 349 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2014 | 964 | 0.030 |
Why?
|
| Neutropenia | 1 | 2017 | 895 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 907 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2016 | 2008 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2014 | 1137 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2016 | 1041 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2013 | 449 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 2 | 2007 | 879 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 4931 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2016 | 8949 | 0.020 |
Why?
|
| Chemokine CCL7 | 1 | 2009 | 27 | 0.020 |
Why?
|
| Lymphatic System | 1 | 2011 | 253 | 0.020 |
Why?
|
| Thiophenes | 1 | 2014 | 588 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 6171 | 0.020 |
Why?
|
| Autopsy | 1 | 2013 | 1020 | 0.020 |
Why?
|
| Observer Variation | 1 | 2015 | 2593 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 1792 | 0.020 |
Why?
|
| Collagen | 2 | 2009 | 2689 | 0.020 |
Why?
|
| Lymphangiogenesis | 1 | 2010 | 172 | 0.020 |
Why?
|
| Permeability | 1 | 2011 | 738 | 0.020 |
Why?
|
| Benzamides | 1 | 2014 | 1379 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2009 | 433 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 1708 | 0.020 |
Why?
|
| Pressure | 1 | 2012 | 1203 | 0.020 |
Why?
|
| Neutrophils | 1 | 2021 | 3719 | 0.020 |
Why?
|
| Patient Selection | 1 | 2020 | 4215 | 0.020 |
Why?
|
| Molecular Probes | 1 | 2010 | 316 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 3920 | 0.020 |
Why?
|
| Molecular Imaging | 1 | 2015 | 828 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2015 | 1538 | 0.020 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2013 | 871 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 643 | 0.020 |
Why?
|
| Blood Volume | 1 | 2009 | 565 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 2886 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2020 | 3589 | 0.020 |
Why?
|
| Perfusion | 1 | 2012 | 1360 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2015 | 1708 | 0.020 |
Why?
|
| Melanoma | 1 | 2005 | 5510 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2012 | 1200 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2003 | 12208 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 3588 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2009 | 617 | 0.020 |
Why?
|
| Adolescent | 4 | 2019 | 85781 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 2088 | 0.020 |
Why?
|
| Microvessels | 1 | 2010 | 544 | 0.020 |
Why?
|
| Chylothorax | 1 | 2006 | 84 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2009 | 561 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2010 | 1423 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 913 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 2942 | 0.020 |
Why?
|
| Lymphatic Vessels | 1 | 2010 | 353 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2007 | 590 | 0.020 |
Why?
|
| Microcirculation | 1 | 2010 | 1286 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 2889 | 0.020 |
Why?
|
| Contrast Media | 1 | 2018 | 5300 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2012 | 1275 | 0.020 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2006 | 147 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 422 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 5456 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4204 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2019 | 12026 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 2988 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 1915 | 0.020 |
Why?
|
| Laminin | 1 | 2006 | 419 | 0.020 |
Why?
|
| Risk Factors | 2 | 2022 | 72290 | 0.010 |
Why?
|
| Diffusion Chambers, Culture | 1 | 2003 | 50 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 1970 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2013 | 2258 | 0.010 |
Why?
|
| Glucose | 1 | 2016 | 4397 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2013 | 19229 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 2872 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2010 | 1533 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2017 | 4286 | 0.010 |
Why?
|
| Skin Window Technique | 1 | 2002 | 22 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2015 | 9849 | 0.010 |
Why?
|
| Child | 2 | 2022 | 77709 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 17446 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2009 | 2373 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15540 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 2699 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2006 | 835 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 2002 | 441 | 0.010 |
Why?
|
| Transgenes | 1 | 2006 | 1009 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 3846 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 4803 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2006 | 627 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 2006 | 669 | 0.010 |
Why?
|
| Zebrafish | 1 | 2013 | 2994 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2006 | 1850 | 0.010 |
Why?
|
| Cell Separation | 1 | 2007 | 1751 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 3647 | 0.010 |
Why?
|
| Information Dissemination | 1 | 2009 | 1099 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2003 | 880 | 0.010 |
Why?
|
| Solubility | 1 | 2002 | 1085 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2003 | 644 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2010 | 1916 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2006 | 1959 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 2003 | 381 | 0.010 |
Why?
|
| Defective Viruses | 1 | 2000 | 112 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 694 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2002 | 684 | 0.010 |
Why?
|
| Lymphokines | 1 | 2002 | 949 | 0.010 |
Why?
|
| Age Factors | 1 | 2016 | 18370 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2003 | 1341 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2000 | 573 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 871 | 0.010 |
Why?
|
| Clone Cells | 1 | 2002 | 1692 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 15165 | 0.010 |
Why?
|
| Body Weight | 1 | 2009 | 4669 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2002 | 704 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2006 | 1179 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2006 | 2263 | 0.010 |
Why?
|
| Cornea | 1 | 2006 | 1524 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2009 | 2265 | 0.010 |
Why?
|
| Binding Sites | 1 | 2006 | 6114 | 0.010 |
Why?
|
| Hypertension | 1 | 2017 | 8480 | 0.010 |
Why?
|
| Genome, Viral | 1 | 2000 | 667 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2000 | 1586 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 1620 | 0.010 |
Why?
|
| Plasmids | 1 | 2000 | 2307 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 5867 | 0.010 |
Why?
|
| Mutation | 2 | 2013 | 29786 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 15076 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2000 | 1904 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2002 | 3420 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2021 | 77449 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 7722 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 15519 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2006 | 5102 | 0.010 |
Why?
|
| Diet | 1 | 2009 | 7939 | 0.010 |
Why?
|
| Brain | 1 | 2017 | 26385 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 7799 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 4364 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2010 | 15295 | 0.000 |
Why?
|